News Release

Genetic factors may contribute to adverse effects produced by synthetic cannabinoids

Understanding how the body processes synthetic cannabinoids could lead to new treatments

Peer-Reviewed Publication

Experimental Biology

Metabolic Pathways for Synthetic Cannabinoids

image: Researchers are using liquid chromatography tandem-mass spectrometry (LC-MS/MS) to identify and characterize metabolites of synthetic cannabinoids (SCBs). A better understanding of how metabolic pathways transform synthetic cannabinoids can provide information needed to develop new treatments to counteract the drug's effects. view more 

Credit: Anna Radominska-Pandya, University of Arkansas for Medical Sciences

Chicago (April 24, 2017) - Synthetic cannabinoid abuse is a growing problem in the United States, with new versions of the drugs coming on the market every year. New research is examining how the body processes these man-made drugs and the role that genetics might play in their metabolism. The work could reveal genetic factors that increase a person's risk for experiencing the most dangerous effects of these drugs and lead to new treatments to counteract those effects.

Anna Radominska-Pandya, PhD, professor at the University of Arkansas for Medical Sciences, will present new research examining the toxicity and mechanisms of action for synthetic cannabinoids at the American Society for Pharmacology and Experimental Therapeutics annual meeting during the Experimental Biology 2017 meeting, to be held April 22-26 in Chicago.

Drugs in the synthetic cannabinoid class--also known as K2, Spice, synthetic marijuana and many other names--come in more than 150 chemical forms. Although these drugs produce mind-altering effects by interacting with the same receptors responsible for the psychoactive effects of marijuana, synthetic cannabinoids can act on the brain in a much stronger way and have unpredictable effects that sometimes lead to severe injury and death.

"The growing interest in these products, which are inappropriately labeled as 'synthetic marijuana,' is due to rampant availability, ability to elude detection in standard drug tests, low price and the misconception that these products are not toxic," said Radominska-Pandya. "Due to potentially fatal effects of synthetic cannabinoids, it is important to understand the biological activity and toxicity of these novel compounds so that effective treatments and antidotes can be developed."

Radominska-Pandya's research group has been at the forefront of synthetic cannabinoid research since the group was one of the first to identify and study synthetic cannabinoids in the United States a decade ago. They have made important discoveries regarding potential molecular mechanisms responsible for the longer-acting and stronger effects of synthetic cannabinoids compared with marijuana, findings that may lead to potential antidotes for counteracting the drugs' most dangerous effects.

Most recently, Radominska-Pandya and her colleagues identified the role of certain enzymes in the metabolism of various synthetic cannabinoids. Results from analyzing synthetic cannabinoid metabolites led the researchers to hypothesize that genetic variation could produce metabolism defects that may cause severe effects when using the drug. This research could eventually lead to a way to identify people who can't metabolize and excrete synthetic cannabinoids and thus have the highest risk for experiencing severe or even deadly outcomes from its use.

As new compounds that are chemically distinct from earlier drugs continue to appear on the market, the researchers plan to investigate the pharmacological effects of these new synthetic cannabinoids and determine how the body's metabolism may contribute to their toxicology.

"Our overall goal is to understand the molecular and behavioral pharmacology and metabolism of these compounds as a means to identify effective therapeutic strategies against their acute and chronic toxic effects in people," said Radominska-Pandya.

Anna Radominska-Pandya will present this research at 12:30-2:30 p.m. Monday, April 24, in Hall F, McCormick Place Convention Center (poster D6 811.1) (abstract). Contact the media team for more information or to obtain a free press pass to attend the meeting.


Image available.

About Experimental Biology 2017

Experimental Biology is an annual meeting comprised of more than 14,000 scientists and exhibitors from six host societies and multiple guest societies. With a mission to share the newest scientific concepts and research findings shaping clinical advances, the meeting offers an unparalleled opportunity for exchange among scientists from across the United States and the world who represent dozens of scientific areas, from laboratory to translational to clinical research. #expbio

About the American Society for Pharmacology and Experimental Therapeutics (ASPET)

ASPET is a 5,100 member scientific society whose members conduct basic and clinical pharmacological research within the academic, industrial and government sectors. Our members discover and develop new medicines and therapeutic agents that fight existing and emerging diseases, as well as increase our knowledge regarding how therapeutics affects humans.

Find more news briefs and tipsheets at:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.